PREPARE
A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib or avelumab + axitinib in first line therapy
III
interventionell
National
Sunitinib, Pembrolizumab, Axitinib, Avelumab
Status: In Rekrutierung
Zeitraum
2017
2023
Zentren
100
Zentren gesucht
Patienten
430
73
11.04.2022
Klinische Settings
1st line
palliativ
Identifier
AIO-NZK-0115ass
AIO-NZK-0115ass
2016-000399-28
Kontakt
Leitung
Prof. Dr. med. Viktor Grünwald
Ansprechpartner*in
Johanna Homfeld
Telefon +49 30 814534472
E-Mail PREPARE@aio-studien-ggmbh.de